Traws Pharma Files 8-K: Other Events & Exhibits
Ticker: TRAW · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, company-update
Related Tickers: ONVO
TL;DR
Traws Pharma (fka Onconova) filed an 8-K. Details TBD.
AI Summary
Traws Pharma, Inc. filed an 8-K on October 14, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Onconova Therapeutics, Inc., is incorporated in Delaware and based in Newtown, PA. This filing does not contain specific financial figures or details about the "Other Events."
Why It Matters
This 8-K filing indicates that Traws Pharma, Inc. has made a regulatory submission to the SEC, which may contain important updates or disclosures for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate disclosed material financial impact.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Onconova Therapeutics, Inc. (company) — Former company name
- October 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- PA (state) — State of business address
- 18940 (zip_code) — Zip code of business address
- 267-759-3680 (phone_number) — Business phone number
FAQ
What specific 'Other Events' are being reported by Traws Pharma, Inc. in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
What is the significance of filing 'Financial Statements and Exhibits' in this 8-K?
This indicates that the company is providing updated financial information or exhibits as required by the SEC, though the content of these is not detailed in the excerpt.
When did Traws Pharma, Inc. change its name from Onconova Therapeutics, Inc.?
The filing lists multiple dates for name changes from Onconova Therapeutics, Inc., including May 26, 2009, and December 26, 2000.
What is Traws Pharma, Inc.'s primary industry based on its SIC code?
Traws Pharma, Inc. is classified under Pharmaceutical Preparations with SIC code 2834.
Where is Traws Pharma, Inc. headquartered?
Traws Pharma, Inc. is located at 12 Penns Trail, Newtown, PA 18940.
Filing Stats: 647 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2025-10-14 07:00:53
Filing Documents
- tm2528641d2_8k.htm (8-K) — 26KB
- tm2528641d2_ex99-1.htm (EX-99.1) — 16KB
- tm2528641d2_ex99-1img001.jpg (GRAPHIC) — 13KB
- 0001104659-25-098994.txt ( ) — 227KB
- tmb-20251014.xsd (EX-101.SCH) — 3KB
- tmb-20251014_lab.xml (EX-101.LAB) — 33KB
- tmb-20251014_pre.xml (EX-101.PRE) — 22KB
- tm2528641d2_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On October 14, 2025, Traws Pharma, Inc. (the "Company") issued a press release (the "Press Release") announcing the dosing of the first subject in its Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects. A copy of the Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated by reference into this Item 8.01.
Forward-Looking Statements
Forward-Looking Statements This Current Report, including Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes," "will" and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.
Forward-looking statements
Forward-looking statements in this Current Report, including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company's business and the accuracy of the forward-looking statements contained herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 14, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 14, 2025 TRAWS PHARMA, INC. By: /s/ Iain Dukes Iain Dukes Chief Executive Officer